CatalYm GmbH
CMC Consulting

CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment, thus making tumors accessible and susceptible again for the patient‘s own immune system. CatalYm was founded in 2016 and is located in Martinsried near Munich. Their lead candidate is currently in phase 1 clinical studies.

CatalYm appointed Gregor Dudziak as external Head of CMC:

In part-time function, Gregor Dudziak is working with CatalYm to manage their CMO and mitigate operational CMC risks, to support Clinical Operations with regard to drug product supply and administration equipment, and to maintain inspection readiness.